Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
Stephanie Fradette, PhD
Advertisement
Articles by Stephanie Fradette, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Efficacy and Safety Data for Tavapadon as an Emerging Therapy in Parkinson’s Disease
2
Investigational COYA 302 Shows Feasibility, Preliminary Efficacy in Small Trial of Frontotemporal Dementia
3
Efgartigimod Application Submitted for Seronegative gMG, EC Approves High-Dose Nusinersen, Copper Histidinate Gains First Approval for Menkes Disease
4
EP. 3 Study Limitations of Evaluating Depression in Youth with Epilepsy
5